scholarly journals Inferences from dysregulated long non-coding RNA-mediated competing endogenous RNAs in various chemotherapy drugs and evaluation of drug response in breast cancer

2020 ◽  
Author(s):  
Ziwen Zhang ◽  
Dongbo Li ◽  
Han Zhang ◽  
Qi Qin ◽  
Qingyuan Zhang
Keyword(s):  
Breast Cancer ◽  
Drug Response ◽  
Treatment Strategies ◽  
Molecular Characteristics ◽  
Cancer Hallmarks ◽  
Chemotherapy Drugs ◽  
Non Coding Rna ◽  
Competing Endogenous Rnas ◽  
Novel Treatment Strategies ◽  
Long Non Coding Rna

Abstract Backgroud: Differences in individual drug response, especially drug resistance, present an obstacle to the treatment of breast cancer (BRCA). Thus, the ability to predict drug response would contribute to developing novel treatment strategies. Accumulating evidence have suggested that tumor molecular profiles and drug response data provide opportunities and challenges for the discovery of new molecular characteristics and mechanisms of drug response in BRCA. Methods: In the present study, an integrated pipeline was developed to explore drug response-related long non-coding RNA (lncRNA)-mediated competing endogenous RNAs (ceRNAs) motifs in BRCA. Results: Drug response-specific ceRNAs indicated that lncRNAs play an essential role in various drug treatments for BRCA. Several key drug-resistant and -sensitive dysregulated ceRNAs were identified in Adriamycin, Cytoxan, and Tamoxifen. The interactions in these ceRNAs showed strong correlations in BRCA. Most drug response-related dysregulated ceRNAs were only present in one kind of drug. A number of drug response-related ceRNAs presented diverse dysregulation patterns. We also extracted some key drug response-related lncRNAs, such as HCP5 and FAM182A. These lncRNAs were associated with certain cancer hallmarks and survival in BRCA. Conclusions: Ultimately, understanding the underlying lncRNA-mediated ceRNAs in drug responses will facilitate improved individual reactions to chemotherapy and overall outcomes of BRCA treatment.

scholarly journals Inferences from dysregulated long non-coding RNA-mediated competing endogenous RNAs in various chemotherapy drugs and evaluation of drug response in breast cancer

2020 ◽  
Author(s):  
Ziwen Zhang ◽  
Dongbo Li ◽  
Han Zhang ◽  
Qi Qin ◽  
Qingyuan Zhang
Keyword(s):  
Breast Cancer ◽  
Drug Response ◽  
Treatment Strategies ◽  
Molecular Characteristics ◽  
Cancer Hallmarks ◽  
Chemotherapy Drugs ◽  
Non Coding Rna ◽  
Competing Endogenous Rnas ◽  
Novel Treatment Strategies ◽  
Long Non Coding Rna

Abstract Backgroud: Differences in individual drug response, especially drug resistance, present an obstacle to the treatment of breast cancer (BRCA). Thus, the ability to predict drug response would contribute to developing novel treatment strategies. Accumulating evidence have suggested that tumor molecular profiles and drug response data provide opportunities and challenges for the discovery of new molecular characteristics and mechanisms of drug response in BRCA. Methods: In the present study, an integrated pipeline was developed to explore drug response-related long non-coding RNA (lncRNA)-mediated competing endogenous RNAs (ceRNAs) motifs in BRCA. Results: Drug response-specific ceRNAs indicated that lncRNAs play an essential role in various drug treatments for BRCA. Several key drug-resistant and -sensitive dysregulated ceRNAs were identified in Adriamycin, Cytoxan, and Tamoxifen. The interactions in these ceRNAs showed strong correlations in BRCA. Most drug response-related dysregulated ceRNAs were only present in one kind of drug. A number of drug response-related ceRNAs presented diverse dysregulation patterns. We also extracted some key drug response-related lncRNAs, such as HCP5 and FAM182A. These lncRNAs were associated with certain cancer hallmarks and survival in BRCA. Conclusions: Ultimately, understanding the underlying lncRNA-mediated ceRNAs in drug responses will facilitate improved individual reactions to chemotherapy and overall outcomes of BRCA treatment.

scholarly journals Inferences From Dysregulated Long Non-Coding RNA-Mediated Competing Endogenous RNAs in Various Chemotherapy Drugs and Evaluation of Drug Response in Breast Cancer

2020 ◽  
Author(s):  
Ziwen Zhang ◽  
Dongbo Li ◽  
Han Zhang ◽  
Qi Qin ◽  
Qingyuan Zhang
Keyword(s):  
Breast Cancer ◽  
Drug Response ◽  
Treatment Strategies ◽  
Molecular Characteristics ◽  
Cancer Hallmarks ◽  
Chemotherapy Drugs ◽  
Non Coding Rna ◽  
Competing Endogenous Rnas ◽  
Novel Treatment Strategies ◽  
Long Non Coding Rna

Abstract Backgroud: Differences in individual drug response, especially drug resistance, present an obstacle to the treatment of breast cancer (BRCA). Thus, the ability to predict drug response would contribute to developing novel treatment strategies. Accumulating evidence have suggested that tumor molecular profiles and drug response data provide opportunities and challenges for the discovery of new molecular characteristics and mechanisms of drug response in BRCA. Methods: In the present study, an integrated pipeline was developed to explore drug response-related long non-coding RNA (lncRNA)-mediated competing endogenous RNAs (ceRNAs) motifs in BRCA. Results: Drug response-specific ceRNAs indicated that lncRNAs play an essential role in various drug treatments for BRCA. Several key drug-resistant and -sensitive dysregulated ceRNAs were identified in Adriamycin, Cytoxan, and Tamoxifen. The interactions in these ceRNAs showed strong correlations in BRCA. Most drug response-related dysregulated ceRNAs were only present in one kind of drug. A number of drug response-related ceRNAs presented diverse dysregulation patterns. We also extracted some key drug response-related lncRNAs, such as HCP5 and FAM182A. These lncRNAs were associated with certain cancer hallmarks and survival in BRCA. Conclusions: Ultimately, understanding the underlying lncRNA-mediated ceRNAs in drug responses will facilitate improved individual reactions to chemotherapy and overall outcomes of BRCA treatment.

scholarly journals Long Non-Coding RNA HOTAIR in Breast Cancer Therapy

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1197 ◽  
Author(s):  
Monica Cantile ◽  
Maurizio Di Bonito ◽  
Margherita Cerrone ◽  
Francesca Collina ◽  
Michelino De Laurentiis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Cancer Progression ◽  
Experimental Studies ◽  
Treatment Strategies ◽  
Cancer Type ◽  
Metastatic Progression ◽  
Aberrant Expression ◽  
Non Coding Rna ◽  
Long Non Coding Rna

Breast cancer (BC) is the most common cancer type among women, and morbidity and mortality rates are still very high. Despite new innovative therapeutic approaches for all BC molecular subtypes, the discovery of new molecular biomarkers involved in tumor progression has been fundamental for the implementation of personalized treatment strategies and improvement of patient management. Many experimental studies indicate that long non-coding RNAs (lncRNAs) are strongly involved in BC initiation, metastatic progression, and drug resistance. In particular, aberrant expression of HOX transcript antisense intergenic RNA (HOTAIR) lncRNA plays an important role in BC contributing to its progression and represents a predictor of BC metastasis. For its proven prognostic value, HOTAIR could represent a potential therapeutic target in BC. In the present review, we summarize the role of HOTAIR in cancer progression and drug resistance, in particular in BC, and we illustrate the main approaches for silencing it.

Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer

2019 ◽  
Vol 97 (2) ◽  
pp. 158-164 ◽  
Author(s):  
Dongfeng Wang ◽  
Jian Li ◽  
Fengling Cai ◽  
Zhi Xu ◽  
Li Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Malignant Disease ◽  
Triple Negative ◽  
Patient Survival ◽  
Predictive Biomarker ◽  
Molecular Characteristics ◽  
Non Coding Rna ◽  
Sense Strand ◽  
Long Non Coding Rna

Breast cancer is the most frequent malignant disease in women worldwide. It is a heterogeneous and complex genetic disease with different molecular characteristics. MAPT-AS1, a long non-coding RNA (lncRNA) existing at the anti-sense strand of the MAPT (microtubule associated protein tau) promoter region, was believed to regulate MAPT, which was associated with disease state in Parkinson’s disease. But the role of MAPT-AS1 in breast cancer has never been reported. In our study we found that MAPT-AS1 is overexpressed in breast cancer but not in triple negative breast cancer (TNBC), and that high expression of MAPT-AS1 was correlated with better patient survival. In addition, the level of MAPT-AS1 was correlated with the expression of MAPT, and MAPT was associated with survival time in breast cancer. Our study suggests that MAPT-AS1 may play a role and be a potential survival predictive biomarker in breast cancer.

CASC15：A tumor-associated long non-coding RNA

2020 ◽  
Vol 26 ◽  
Author(s):  
Bei Wang ◽  
Wen Xu ◽  
Yuxuan Cai ◽  
Chong Guo ◽  
Gang Zhou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Therapeutic Target ◽  
Cancer Colorectal ◽  
Tumor Development ◽  
Pathophysiological Mechanism ◽  
Biological Processes ◽  
Non Coding Rna ◽  
Cancer Côlon ◽  
The Relationship ◽  
Long Non Coding Rna

Background: CASC15, one of long non-coding RNA, is involved in the regulation of many tumor biological processes, and is expected to become a new biological therapeutic target. This paper aims to elucidate the pathophysiological function of CASC15 in various tumors. Methods: The relationship between CASC15 and tumors was analyzed by searching references, and summarizes the specific pathophysiological mechanism of CASC15. Results: LncRNA CASC15 is closely related to tumor development, and has been shown to be abnormally high expressed in all kinds of tumors, including breast cancer, cervical cancer, lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, colon cancer, colorectal cancer, cardiac hypertrophy, intrahepatic cholangiocarcinoma, leukemia, melanoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma. However, CASC15 has been found to be downexpressed abnormally in ovarian cancer, glioma and neuroblastoma. Besides, it is identified that CASC15 can affect the proliferation, invasion and apoptosis of tumors. Conclusion: LncRNA CASC15 has the potential to become a new therapeutic target or marker for a variety of tumors.

scholarly journals Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1

Oncogene ◽  
2021 ◽  
Author(s):  
Yina Qiao ◽  
Ting Jin ◽  
Shengdong Guan ◽  
Shaojie Cheng ◽  
Siyang Wen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Noncoding Rna ◽  
Causes Of Death ◽  
Invasion And Metastasis ◽  
Lymphatic Metastases ◽  
Non Coding Rna ◽  
Promising Target ◽  
Mesenchymal Transformation ◽  
Long Non Coding Rna ◽  
Mcf 7

AbstractInvasion and metastasis are the leading causes of death in patients with breast cancer (BC), and epithelial-mesenchymal transformation (EMT) plays an essential role in this process. Here, we found that Lnc-408, a novel long noncoding RNA (lncRNA), is significantly upregulated in BC cells undergoing EMT and in BC tumor with lymphatic metastases compared with those without lymphatic metastases. Lnc-408 can enhance BC invasion and metastasis by regulating the expression of LIMK1. Mechanistically, Lnc-408 serves as a sponge for miR-654-5p to relieve the suppression of miR-654-5p on its target LIMK1. Knockdown or knockout of Lnc-408 in invasive BC cells clearly decreased LIMK1 levels, and ectopic Lnc-408 in MCF-7 cells increased LIMK1 expression to promote cell invasion. Lnc-408-mediated enhancement of LIMK1 plays a key role in cytoskeletal stability and promotes invadopodium formation in BC cells via p-cofilin/F-actin. In addition, the increased LIMK1 also facilitates the expression of MMP2, ITGB1, and COL1A1 by phosphorylating CREB. In conclusion, our findings reveal that Lnc-408 promotes BC invasion and metastasis via the Lnc-408/miR-654-5p/LIMK1 axis, highlighting a novel promising target for the diagnosis and treatment of BC.

Targeting long non-coding RNA ASBEL with oligonucleotide antagonist for breast cancer therapy

2017 ◽  
Vol 489 (4) ◽  
pp. 386-392 ◽  
Author(s):  
Yang Xia ◽  
Xiangqian Xiao ◽  
Xiongwei Deng ◽  
Fang Zhang ◽  
Xiaofei Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Breast Cancer Therapy ◽  
Non Coding Rna ◽  
Long Non Coding Rna

Screening and survival analysis of melanoma immunodrug response-related genes and the function of magnetic nanoparticles in gene extraction

2021 ◽  
Vol 11 (8) ◽  
pp. 1306-1312
Author(s):  
Li Song ◽  
Ningchao Du ◽  
Haitao Luo ◽  
Furong Li
Keyword(s):  
Survival Analysis ◽  
Magnetic Nanoparticles ◽  
Drug Response ◽  
High Throughput Sequencing ◽  
Cox Proportional Hazards ◽  
Sequencing Data ◽  
Protein Coding ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Rna Genes

This study aimed to identify the association of protein coding and long non coding RNA genes with immunotherapy response in melanoma. Based on RNA sequencing data of melanoma specimens, the expression levels of protein coding and long non coding RNA genes were calculated using the Kallisto RNA-seq quantification method, and differently expressed genes were detected using the DESeq2 method. Cox proportional hazards regression was used to evaluate the effects of gene expression on survival. According to the clinical data of 14 patients with drug response and 11 patients without drug response, 18 protein coding genes and 14 long non coding RNAs showed differential expressions (multiple of difference > 2 and P < 0.01 after correction), among which the coding genes of differential expression were significantly enriched through the process of cell adhesion (P < 0.01). The results of survival analysis showed that 18 coding genes and 14 long non coding RNA genes had significant effects on patient survival (P < 0.01). In this study, magnetic nanoparticles can be used to extract genomic DNA and total RNA due to their paramagnetism and biocompatibility, then transcriptome high-throughput sequencing was performed. The method has the advantages of removing dangerous reagents such as phenol and chloroform, replacing inorganic coating such as silica with organic oil, and shortening reaction time. Protein coding and long non coding RNA genes as well as magnetic nanoparticles may serve as potential cancer immune biomarker targets for developing future oncological treatments.

Sign in / Sign up

Export Citation Format

Share Document